{"pmid": "11533366", "sentences": {"sent_1": {"Section": "", "text": "DESIGN AND STATISTICAL ANALYSIS : We conducted a double - blind , multicenter , multinational study at 93 centers worldwide : including 56 in the United States , and 21 in countries in Africa , Australia , Europe , North America , and South America .", "entities": {"entity_1": {"text": "United States", "class": "Intervention", "negation": 0, "UMLS": "", "index": 1, "start": 25}, "entity_2": {"text": "countries", "class": "Participant", "negation": 0, "UMLS": "", "index": 2, "start": 31}, "entity_3": {"text": "South America", "class": "Participant", "negation": 0, "UMLS": "", "index": 3, "start": 43}}, "relations": {}}, "sent_2": {"Section": "", "text": "In this study , we randomly assigned 689 patients ( aged 2 - 5 years ) to 12 weeks of treatment with placebo ( 228 patients ) or 4 mg of montelukast as a chewable tablet ( 461 patients ) after a 2 - week placebo baseline period .", "entities": {"entity_4": {"text": "placebo", "class": "Intervention", "negation": 0, "UMLS": "C0032042:placebo,", "index": 1, "start": 22}, "attribute_1": {"text": "4 mg", "class": "measure", "negation": 0, "UMLS": "", "index": 2, "start": 28}, "entity_5": {"text": "montelukast", "class": "Intervention", "negation": 0, "UMLS": "C0298130:montelukast,", "index": 3, "start": 31}, "entity_6": {"text": "placebo", "class": "Intervention", "negation": 0, "UMLS": "C0032042:placebo,", "index": 4, "start": 45}}, "relations": {}}, "sent_3": {"Section": "", "text": "Patients had a history of physician - diagnosed asthma requiring use of beta-agonist and a predefined level of daytime asthma symptoms .", "entities": {"entity_7": {"text": "diagnosed asthma", "class": "Participant", "negation": 0, "UMLS": "C0011900:diagnosed,C0004096:asthma,", "index": 1, "start": 7}, "entity_8": {"text": "daytime asthma symptoms", "class": "Outcome", "negation": 0, "UMLS": "C1457887:symptoms,C0004096:asthma,", "index": 2, "start": 18}}, "relations": {}}, "sent_4": {"Section": "", "text": "Caregivers answered questions twice daily on a validated , asthma-specific diary card and , at specified times during the study , completed a validated asthma-specific quality - of - life questionnaire .", "entities": {"entity_9": {"text": "Caregivers", "class": "Participant", "negation": 0, "UMLS": "", "index": 1, "start": 0}}, "relations": {}}, "sent_5": {"Section": "", "text": "Physicians and caregivers completed a global evaluation of asthma control at the end of the study .", "entities": {"entity_10": {"text": "Physicians", "class": "Participant", "negation": 0, "UMLS": "C0804815:Physician,", "index": 1, "start": 0}, "entity_11": {"text": "caregivers", "class": "Participant", "negation": 0, "UMLS": "", "index": 2, "start": 2}, "entity_12": {"text": "global evaluation of asthma control", "class": "Outcome", "negation": 0, "UMLS": "C0220825:evaluation,C0004096:asthma,", "index": 3, "start": 5}}, "relations": {}}, "sent_6": {"Section": "", "text": "Efficacy end points included : daytime and overnight asthma symptoms , daily use of beta-agonist , days without asthma , frequency of asthma attacks , number of patients discontinued because of asthma , need for rescue medication , physician and caregiver global evaluations of change , asthma-specific caregiver quality of life , and peripheral blood eosinophil counts .", "entities": {"entity_13": {"text": "daytime", "class": "Outcome", "negation": 0, "UMLS": "", "index": 1, "start": 5}, "entity_14": {"text": "overnight asthma symptoms", "class": "Outcome", "negation": 0, "UMLS": "C1457887:symptoms,C0004096:asthma,", "index": 2, "start": 7}, "entity_15": {"text": "daily use of beta-agonist", "class": "Outcome", "negation": 0, "UMLS": "C2987634:agonist,", "index": 3, "start": 11}, "entity_16": {"text": "days without asthma", "class": "Outcome", "negation": 0, "UMLS": "C0004096:asthma,", "index": 4, "start": 16}, "entity_17": {"text": "frequency of asthma attacks", "class": "Outcome", "negation": 0, "UMLS": "C0347950:asthma attacks,", "index": 5, "start": 20}, "entity_18": {"text": "number of patients discontinued because of asthma", "class": "Outcome", "negation": 0, "UMLS": "C0004096:asthma,C2360800:Number of patients,C1444662:Discontinued,", "index": 6, "start": 25}, "entity_19": {"text": "rescue medication", "class": "Outcome", "negation": 0, "UMLS": "C0013227:medication,", "index": 7, "start": 35}, "entity_20": {"text": "physician and caregiver global evaluations of change", "class": "Outcome", "negation": 0, "UMLS": "C0220825:evaluations,", "index": 8, "start": 38}, "entity_21": {"text": "asthma-specific caregiver quality of life", "class": "Outcome", "negation": 0, "UMLS": "C0518214:quality of life,C1552740:specific,C0004096:asthma,", "index": 9, "start": 46}, "entity_22": {"text": "peripheral blood eosinophil counts", "class": "Outcome", "negation": 0, "UMLS": "C0229664:peripheral blood,C0200638:eosinophil count,", "index": 10, "start": 53}}, "relations": {}}, "sent_7": {"Section": "", "text": "Although exploratory , the efficacy end points were predefined and their analyses were written in a data analysis plan before study unblinding .", "entities": {"entity_23": {"text": "efficacy", "class": "Outcome", "negation": 0, "UMLS": "", "index": 1, "start": 4}}, "relations": {}}, "sent_8": {"Section": "", "text": "At screening and at study completion , a complete physical examination was performed .", "entities": {}, "relations": {}}, "sent_9": {"Section": "", "text": "Routine laboratory tests were drawn at screening and weeks 6 and 12 , and submitted to a central laboratory for analysis .", "entities": {}, "relations": {}}, "sent_10": {"Section": "", "text": "Adverse effects were collected from caregivers at each clinic visit .", "entities": {"entity_24": {"text": "Adverse effects", "class": "Outcome", "negation": 0, "UMLS": "C0879626:Adverse effects,", "index": 1, "start": 0}, "entity_25": {"text": "caregivers", "class": "Participant", "negation": 0, "UMLS": "", "index": 2, "start": 5}}, "relations": {}}, "sent_11": {"Section": "", "text": "An intention - to - treat approach , including all patients with a baseline measurement and at least 1 postrandomization measurement , was performed for all efficacy end points .", "entities": {"entity_26": {"text": "intention - to - treat approach", "class": "Intervention", "negation": 0, "UMLS": "C0162425:intention,", "index": 1, "start": 1}, "entity_27": {"text": "efficacy", "class": "Outcome", "negation": 0, "UMLS": "", "index": 2, "start": 26}}, "relations": {}}, "sent_12": {"Section": "", "text": "An analysis - of - variance model with terms for treatment , study center and stratum ( inhaled / nebulized corticosteroid use , cromolyn use , or none ) was used to estimate treatment group means and between - group differences and to construct 95 % confidence intervals .", "entities": {"entity_28": {"text": "stratum", "class": "Outcome", "negation": 0, "UMLS": "", "index": 1, "start": 15}, "entity_29": {"text": "inhaled / nebulized corticosteroid", "class": "Intervention", "negation": 0, "UMLS": "C0001617:corticosteroid,C0004048:inhaled,", "index": 2, "start": 17}, "entity_30": {"text": "cromolyn use", "class": "Intervention", "negation": 0, "UMLS": "C0086073:cromolyn,", "index": 3, "start": 23}}, "relations": {}}, "sent_13": {"Section": "", "text": "Treatment - by - age , - sex , - race , - radioallergosorbent test , - stratum , and - study center interactions were evaluated by including each term separately .", "entities": {"entity_31": {"text": "stratum", "class": "Outcome", "negation": 0, "UMLS": "", "index": 1, "start": 17}, "entity_32": {"text": "- study center interactions", "class": "Outcome", "negation": 0, "UMLS": "C0947630:study,C0037420:interaction,", "index": 2, "start": 20}}, "relations": {}}, "sent_14": {"Section": "", "text": "Fisher 's exact test was used for between - group comparisons of the frequency of asthma attacks , discontinuations from the study because of worsening asthma , need for rescue medication , and the frequencies of adverse effects .", "entities": {"entity_33": {"text": "Fisher 's exact test", "class": "Intervention", "negation": 0, "UMLS": "C0392366:test,", "index": 1, "start": 0}, "entity_34": {"text": "frequency of asthma attacks", "class": "Outcome", "negation": 0, "UMLS": "C0347950:asthma attacks,", "index": 2, "start": 13}, "entity_35": {"text": "worsening asthma", "class": "Participant", "negation": 0, "UMLS": "C0004096:asthma,", "index": 3, "start": 24}, "entity_36": {"text": "rescue medication", "class": "Outcome", "negation": 0, "UMLS": "C0013227:medication,", "index": 4, "start": 29}, "entity_37": {"text": "frequencies of adverse effects", "class": "Outcome", "negation": 0, "UMLS": "C0879626:adverse effects,", "index": 5, "start": 34}}, "relations": {}}, "sent_15": {"Section": "", "text": "Because of an imbalance in baseline values for eosinophil counts for the 2 treatment groups , an analysis of covariance was performed on the eosinophil change from baseline with the patient 's baseline as covariate .", "entities": {"attribute_2": {"text": "imbalance", "class": "modifier", "negation": 0, "UMLS": "C1397014:imbalance,", "index": 1, "start": 3}, "entity_38": {"text": "eosinophil counts", "class": "Outcome", "negation": 0, "UMLS": "C0200638:eosinophil count,", "index": 2, "start": 8}, "entity_39": {"text": "eosinophil change", "class": "Outcome", "negation": 0, "UMLS": "C0014457:eosinophilia,", "index": 3, "start": 24}}, "relations": {}}}}